Korean Circ J.
2024 Dec;54(12):767-793. 10.4070/kcj.2024.0257.
2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes
- Kim HK
1 - Ryoo S2
- Lee SH3
- Hwang D4
- Choi KH5
- Park J2
- Lee HJ2
- Yoon CH6
- Lee JH7,8
- Hahn JY5
- Hong YJ3
- Hwang JY9
- Jeong MH3,10
- Park DA2
- Nam CW11
- Kim W12
- Affiliations
-
- 1Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea
- 2Division of Healthcare Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea
- 3Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
- 4Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul National University of College of Medicine, Seoul, Korea
- 5Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 6Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea
- 7Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea
- 8School of Medicine, Kyungpook National University, Daegu, Korea
- 9Department of Internal Medicine, College of Medicine, Gyeongsang National University and Gyeongsang National University Hospital, Jinju, Korea
- 10Department of Cardiovascular Medicine, Gwangju Veterans Hospital, Gwangju, Korea
- 11Department of Medicine, Keimyung University Dongsan Hospital, Daegu, Korea
- 12Department of Cardiovascular Medicine, Kyung Hee University Hospital, Seoul, Korea
- KMID: 2563793
- DOI: http://doi.org/10.4070/kcj.2024.0257
Abstract
- Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National EvidenceBased Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Pharmacotherapy for acute myocardial infarction
- Evidence-based Healthcare in Korea
- Primary Coronary Stenting as a Successful Treatment of Acute Myocardial
- Clinical Study on Kawasaki Disease for Evidence-based Treatment
- Percutaneous Cardiopulmonary Support in Refractory No-Reflow with Cardiogenic Shock after Coronary Stenting in Acute Myocardial Infarction
